These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33509675)

  • 1. Ketamine for Depression in Older Adults.
    Subramanian S; Lenze EJ
    Am J Geriatr Psychiatry; 2021 Sep; 29(9):914-916. PubMed ID: 33509675
    [No Abstract]   [Full Text] [Related]  

  • 2. Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight.
    Singh I; Morgan C; Curran V; Nutt D; Schlag A; McShane R
    Lancet Psychiatry; 2017 May; 4(5):419-426. PubMed ID: 28395988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketamine helps a third of patients with treatment resistant depression, finds small UK study.
    Torjesen I
    BMJ; 2014 Apr; 348():g2576. PubMed ID: 24699320
    [No Abstract]   [Full Text] [Related]  

  • 4. Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective.
    López-Díaz Á; Murillo-Izquierdo M; Moreno-Mellado E
    Br J Psychiatry; 2019 Aug; 215(2):447-448. PubMed ID: 31030677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esketamine as a treatment for paediatric depression: questions of safety and efficacy.
    Zimmermann KS; Richardson R; Baker KD
    Lancet Psychiatry; 2020 Oct; 7(10):827-829. PubMed ID: 31952957
    [No Abstract]   [Full Text] [Related]  

  • 6. [Ketamine--a new treatment option for therapy-resistant depression].
    Köhler S; Betzler F
    Fortschr Neurol Psychiatr; 2015 Feb; 83(2):91-7. PubMed ID: 25723773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter to the editor: Are ketamine-induced subjective bodily experiences associated with antidepressant effects? A sensation of floating and a sensation of lightness are not the same - A comment on Acevedo-Diaz et al.
    Stocker K; Hasler G; Hartmann M
    J Psychiatr Res; 2021 May; 137():454-455. PubMed ID: 33798971
    [No Abstract]   [Full Text] [Related]  

  • 8. Ketamine: Future Treatment For Unresponsive Depression?
    Frere M; Tepper J
    Ir Med J; 2016 Sep; 109(8):453. PubMed ID: 28124853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development.
    Frye MA; Blier P; Tye SJ
    J Clin Psychopharmacol; 2015 Jun; 35(3):334-6. PubMed ID: 25928701
    [No Abstract]   [Full Text] [Related]  

  • 10. Esketamine for treatment resistant depression: a trick of smoke and mirrors?
    Gastaldon C; Papola D; Ostuzzi G; Barbui C
    Epidemiol Psychiatr Sci; 2019 Dec; 29():e79. PubMed ID: 31841104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting.
    Nikayin S; Rhee TG; Cunningham ME; de Fontnouvelle CA; Ostroff RB; Sanacora G; Wilkinson ST
    JAMA Psychiatry; 2022 Jul; 79(7):736-738. PubMed ID: 35544190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression.
    Pérez-Esparza R; Kobayashi-Romero LF; García-Mendoza AM; Lamas-Aguilar RM; Fonseca-Perezamador A
    Acta Psychiatr Scand; 2019 Aug; 140(2):182-183. PubMed ID: 31251388
    [No Abstract]   [Full Text] [Related]  

  • 13. Ketamine for treatment-resistant depression: ready or not for clinical use?
    Rush AJ
    Am J Psychiatry; 2013 Oct; 170(10):1079-81. PubMed ID: 23982324
    [No Abstract]   [Full Text] [Related]  

  • 14. Ineffectiveness of Repeated Intravenous Ketamine Infusions in Treatment-Resistant Depression After a Post-Ketamine Relapse: Time for a Rethink?
    López-Díaz Á; Fernández-González JL
    J Clin Psychopharmacol; 2018 Oct; 38(5):534-536. PubMed ID: 30106877
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of Ketamine in Elderly Patients with Treatment-Resistant Depression.
    Medeiros da Frota Ribeiro C; Riva-Posse P
    Curr Psychiatry Rep; 2017 Nov; 19(12):107. PubMed ID: 29138992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esketamine (Spravato) for Treatment-Resistant Depression.
    Jalloh M
    Am Fam Physician; 2020 Mar; 101(6):339-340. PubMed ID: 32163257
    [No Abstract]   [Full Text] [Related]  

  • 17. US Food and Drug Administration approval of esketamine and brexanolone.
    Cristea IA; Naudet F
    Lancet Psychiatry; 2019 Dec; 6(12):975-977. PubMed ID: 31680013
    [No Abstract]   [Full Text] [Related]  

  • 18. Esketamine for resistant depression in older people with cognitive impairment: A case report.
    Romani S; Jacquet B; Cohen D; Curiale V; Laurent I; Louchart De La Chapelle S
    Encephale; 2023 Dec; 49(6):651-653. PubMed ID: 37604711
    [No Abstract]   [Full Text] [Related]  

  • 19. Is ketamine effective and safe for treatment-resistant depression?
    Zorn A; Linn S; Jenkinson M; Neher JO; Safranek S; Kelsberg G
    J Fam Pract; 2021 Apr; 70(3):E1-E3. PubMed ID: 34314342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esketamine More Effective Than Quetiapine for Hard-to-Treat Depression.
    Harris E
    JAMA; 2023 Nov; 330(17):1611. PubMed ID: 37851473
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.